Sentences with phrase «ongoing safety program»

Set up an ongoing safety program that associates can't file away and quickly forget.

Not exact matches

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

In a historic milestone for the drone industry, this week AirMap and Project Wing in a test program led by the Virginia Tech Mid-Atlantic Aviation Partnership, successfully demonstrated an industry - leading solution to safety - critical airspace deconfliction challenges as part of the ongoing NASA - UTM trials.

«The ongoing professional collaboration between the County's Department of Social Services and the Rockland County District Attorney has resulted in the detection of fraud in several Medicaid and other important social safety - net programs,» said Rockland County Executive C. Scott Vanderhoef.

For the new study, Saint and his colleagues from the Patient Safety Enhancement Program, a joint U-M and VA program, surveyed infection control leaders at hospitals, as part of an ongoing project that started iProgram, a joint U-M and VA program, surveyed infection control leaders at hospitals, as part of an ongoing project that started iprogram, surveyed infection control leaders at hospitals, as part of an ongoing project that started in 2005.

Governor Jerry Brown signed the California State Budget for Fiscal Year 2017 - 18, which included an additional $ 50 million in ongoing funding for the After School Education and Safety (ASES) program.

The Department's Disadvantaged Business Enterprise (DBE) program is designed to remedy ongoing discrimination and the continuing effects of past discrimination in federally - assisted highway, transit, airport, and highway safety financial assistance transportation contracting markets nationwide.

«We drew from ongoing education efforts by national and state grooming and styling associations, industry training programs and schools to develop these protocols for animal safety and standards of care.»

We have a regular ongoing testing program in place to further ensure the quality and safety of our products.

A TNR program in Maricopa County, Arizona, called the «Maddie's Pet Rescue Project» was so successful the County Board of Supervisors issued a resolution stating: «Maricopa County Board of Supervisors does hereby endorse non - lethal trap - neuter - return, when accompanied by ongoing feral cat management, as the most effective, humane method of controlling feral cat populations in Maricopa County and in so doing better provides for the welfare of these animals while better serving our communities» public health and safety concerns.»

Ongoing collaboration with cities and other stakeholders to ensure connections to transit, as well as programming that increases access for people in all racial and socio - economic groups such as progressive pricing, hiring commitments, and safety and engagement efforts.

As part of our ongoing effort to provide drivers with low - cost, high quality traffic safety programs, we offer a wide variety of driver improvement courses for several U.S. states.

• Highly experienced in enhancing workplace safety, by conducting regular training programs, to meet the ongoing needs of staff members.

Ongoing drug and alcohol and road safety education programs throughout a child's schooling can build resilience and increase competency in skills needed to be able to make responsible decisions in traffic and drug - related situations.

Ongoing drug and alcohol, and road safety education programs throughout a child's schooling can build students» resilience and increase their competency in skills needed to be able to make responsible decisions in traffic and alcohol and drug - related situations.

Ongoing drug and road safety education programs can build students» resilience and increase their competency in skills needed to be able to make responsible decisions in traffic and drug - related situations.

Safety Program Reimbursement Grant: The goal of the NAR Safety Program Reimbursement Grant is to provide funding assistance to state and local REALTOR ® Associations to help implement a Safety Program or feature for their members, and to encourage ongoing awareness of REALTOR ® Safety.

NAR Safety Reimbursement Grant Program — Introduced this year, the grants provide funding assistance, up to $ 2,500, to state and local REALTOR ® Associations to help implement a Safety Program or initiative for their members, and to encourage ongoing awareness of REALTOR ® Safety.